ClinicalTrials.gg
RecruitingNCT06705543CARDIOMICSUpdated Apr 10, 2025

Antenatal Investigation of Fetuses With Complex Congenital Heart Defects Using multiOMICS

An interventional study of multi-omics genetic analyses included exome and multi-omics genetic analyses in Congenital Heart Disease, sponsored by University Hospital, Bordeaux. Recruiting at 2 sites in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.

Planned enrollment
27th of 34
40 · median 91
Started
2025
with 9 others
No phase
27 of 73
11 open now
Primary completion
2026-06
later than 7 of 21 live
Registered
61st of 73
by date
Lead sponsor
7 of 73
University Hospital, Bordeaux

Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 61st registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Heart Defects, Congenital with a site in France, or all of them as a file.
02

Study summary

This study will use multiOMICS study on fetuses with complexe congenital heart defects (CHD) to identify etiological epigenetic factors of these cardiac malformations, related to environmental factors during pregnancy.

Read the detailed description

Congenital heart defects (CHDs) are a very heterogeneous group of heart diseases in terms of embryonic mechanisms, phenotypes and aetiologies. In isolated forms, genetic causes are identified in only 19% of cases, linked to chromosomal abnormalities (8%) or gene variants (11%). Environmental causes such as infection, exposure to toxic substances or ingestion of teratogenic substances may also favour the onset of MCC. Although in the majority of cases the aetiology remains unknown, the discovery of MCC in the ante-natal period almost systematically leads to a genetic aetiological work-up using amniotic fluid for karyotype, Array-CGH and, more recently, exome analysis. With regard to environmental causes, recent data in the literature report a link between environmental exposures (occupational, extra-occupational or medicinal) and congenital anomalies.

Objectives: The low percentage of genetic abnormalities and toxic factors identified as causal in patients with non-syndromic CHD prompts a search for more complex causes such as epigenetic modifications linked to an interaction between genes and environmental factors.

Methods: The multi-omics study approach, using high-throughput sequencing technologies (exome, RNASeq, methylSeq), provides a wealth of information on cellular and/or tissue signaling pathways in response to exposure. Integrated analysis of transcriptomes and methylomes has demonstrated the occurrence of combined defects in gene expression and methylation following toxic exposure. The period of CHD formation during embryonic development prompts us to look for epigenetic modifications during prenatal period, as close as possible to the pathophysiological mechanisms leading to this malformation.

Expected results: the multi-omics analysis applied to fetuses with non-syndromic complex CHD, combined with the characterization of occupational and non-occupational environmental exposures, will enable us to extend the etiological search for these malformations, to identify biomarkers linked to the occurrence and severity of these malformations and gain a better understanding of the pathophysiological mechanisms linked to CHD.

In the longer term, this study will serve as a basis for large-scale studies to enable the development of prevention policies, based on exhaustive, multicenter cohorts. In addition, multi-omics studies could identify gene markers, by exome, transcriptome and/or methylome, which could then be studied in a targeted manner.

03

Conditions studied

  • Congenital Heart Disease

Keywords

  • Congenital Heart Disease
  • exome
  • RNAseq
  • methylome
  • biomarkers
  • environnemental factors
  • epigenetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Fetuses with congenital heart disease :

  • Pregnant women aged 18 and more
  • Single foetal pregnancy in which the foetus has a complex non-syndromic congenital heart defect, with no identified chromosomal abnormality, gene syndrome or infection.
  • Patient for whom the indication for amniocentesis has been accepted by the CPDPN and accepted by the couple/patient
  • Gestational age between 20 and 28 weeks' gestation.
  • Person affiliated to or benefiting from a social security scheme.
  • Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research).

Control Population for RNAseq and MéthlySeq

  • Pregnant women aged 18 and more
  • Patient in whom the indication for amniocentesis has been retained by the CPDPN and accepted by the couple/patient, for a non-malformative ultrasound anomaly (hyperechoic bowel, idiopathic hydramnios, increased risk of trisomy 21, agenesis of the OPN, suspected toxoplasmosis/CMV seroconversion), with no chromosomal anomaly, gene syndrome or infection identified.
  • Gestational age between 20 and 28 weeks' gestation.
  • Person affiliated to or benefiting from a social security scheme.
  • Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research).

Exclusion criteria

Exclusion Criteria:

For both populations (cases and controls) :

  • Female minors,
  • Patients not affiliated to the social security system,
  • Patients who do not understand French,
  • Patients under guardianship
  • Multiple pregnancies, or where the foetus has associated malformations
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Congenital Heart Defects population

    Genetic: multi-omics genetic analyses included exome

  • Placebo comparator
    control population

    Genetic: multi-omics genetic analyses

Interventions

  • Geneticmulti-omics genetic analyses included exome

    Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit. These genetic analyses will include : * Study of free RNA circulating in the LA, * Methylome study. * Trio exome study (parents-fetus).

  • Geneticmulti-omics genetic analyses

    Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit; These genetic analyses will include : * Study of free RNA circulating in the LA, * Methylome study.

06

What researchers measure

Primary outcomes

  1. Cardiac malformations biomarkers

    Identification of biomarkers such as RNA deregulation (mRNA, LncRNA, miRNA, upregulated or deregulated compared to controls), and DNA methylation marks (present or absent, compared to controls) specific to cardiac malformations by transcriptomic and methylomic analysis of amniotic fluid from fetuses with congenital heart disease

    Time frame: Visit 1 : day 0

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 14 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 26, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06705543
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Apr 1, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 10, 2025

Study contacts

Caroline ROORYCK-THAMBO, PROF
Contact
caroline.rooryck-thambo@chu-bordeaux.fr
+335 56 79 59 81
Caroline ROORYCK-THAMBO, PROF
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion